GlioPharma is a privately-held development stage biopharmaceutical company based in Denmark. We are dedicated to the development of innovative therapies for glioblastoma multiforme (GBM) using the company's unique expertise and proprietary technology. GBM is the most common and most aggressive primary brain tumor. GBM is a devastating disease with marginal life expectancy and limited treatment options, necessitating the development of conceptually new therapeutic strategies.
We are developing a novel therapy aiming to selectively and efficiently kill GBM cells by using a combination of auger-emitter-chemotherapy using convection-enhanced delivery. Our lead compound, currently in preclinical development, has been shown to efficiently deplete cancer cells in animal models of GBM and significantly prolong survival, without apparent effects on host brain. Through further development our lead compound has the potential to provide improved clinical benefit for patients in dire need of new therapeutic options.
The company was founded in 2015 by serial entrepreneurs and Science Venture Denmark and is based on development work by scientists from Odense University Hospital and University of Southern Denmark.
The company's management consists of a dynamic team of academic scientists, experienced drug developers, and business professionals.
Copyright © All Rights Reserved